The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN acute myelogenous leukemia practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version].Rockledge, PA: National Comprehensive Cancer Network; 2001.
2.
TallmanM.S.Therapy of acute myeloid leukemia. Cancer Control.2001; 8: 62–78.
3.
RoweJ.M.What is the best induction regimen for acute myelogenous leukemia?Leukemia.1998; 12(suppl 1): S16–9.
4.
PhillipsG.L., ReeceD.E., ShepherdJ.D.High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood.1991; 77: 1429–35.
5.
WeickJ.K., KopeckyK.J., AppelbaumF.R.A randomized investigation of high-dose vs standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood.1996; 88: 2841–51.
6.
MitusA.J., MillerK.B., SchenkeinD.P.Improved survival for patients with acute myelogenous leukemia. J Clin Oncol.1995; 13: 560–9.
7.
LazarusH.M., VoglerW.R., BurnsC.P.High-dose cytosine arabinsode and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. Cancer.1989; 63: 1055–9.
8.
HerzigR.H.High-dose ara-C in older adults with acute leukemia. Leukemia.1996; 10(suppl 1): S10–11.
9.
BishopJ.F., MatthewsJ.P., YoungG.A.A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood.1996; 87: 1710–7.
10.
LowenthalR.M., BradstockK.F., MatthewsJ.P.A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Leuk Lymphoma.1999; 34: 501–10.
11.
HiddemannW., KreutzmannH., StraifK.High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol.1987; 14(suppl 1): 73–7.
12.
CraigJ.B., PowellB.L., WhiteD.R.Antiemetic therapy in patients treated with high-dose cytosine arabinoside. Oncology.1987; 44: 90–2.
13.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
14.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56: 729–64.
15.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version].Rockledge, PA: National Comprehensive Cancer Network; 2001.
16.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
17.
RazisE., ArlinZ.A., AhmedT.Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol.1994; 91: 171–4.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–85.
20.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–9, 63–7,70–4.
21.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–9.
22.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75: 397–402.
23.
HigaG.M., GockermanJ.P., HuntA.L.The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. Cancer.1991; 68: 1691–3.
HermansC., StraetmansN., MichauxJ.L.Pericarditis induced by highdose cytosine arabinoside chemotherapy. Ann Hematol.1997; 75: 55–7.
26.
ReykdalS., ShamR., KouidesP.Cytarabine-induced pericarditis: A case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res.1995; 19: 141–4.
27.
StentoftJ.The toxicity of cytarabine. Drug Safety.1990; 5: 7–27.
28.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
29.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24: 969–90.
